

Registry Platform Myelofibrosis and Anemia

NCT06976918

Status RECRUITING
Sponsor iOMEDICO AG
Enrollment 200 participants

Key Eligibility Criteria

Inclusion (6)

- Confirmed diagnosis of primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) (Note: diagnosis according to WHO-2017, ICC-2022 or WHO-2022 or IWG-MRT criteria, respectively).
 - Diagnosis of anemia at the time of enrollment as per individual, clinical assessment by the local physician.
 - Start of first or subsequent systemic treatment for MF.
 - Informed consent and registration for the GSG-MPN Bioregistry.
 - Willingness and capability to participate in PRO assessment.
- ... and 1 more (see full listing online)

Exclusion (2)

- No systemic therapy for diagnosed primary or secondary MF.
- Planned allogenic stem cell transplantation (allo-SCT) or active participation in an interventional clinical trial.

Locations (1 total)

Multiple sites all over Germany, Multiple Locations, Germany